SAN DIEGO, November 3, 2016 – Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, today announced that three abstracts detailing preclinical data on P-BCMA-101, the company’s BCMA-specific CAR-T drug candidate, have been selected for presentation at the American Society of Hematology (ASH) Annual Meeting. The studies explore utility and performance of Poseida’s proprietary CAR-T modifications using its piggyBac™ non-viral gene delivery system and Centyrin binding scaffold. Data will be presented at the 2016 ASH Annual Meeting in San Diego on December 3rd and 5th. Abstracts are currently available online at http://www.hematology.org/Annual-Meeting/.

The following abstracts will be presented:

Presentation Title: A Novel BCMA-Specific, Centyrin-Based CAR-T Product for the Treatment of Multiple Myeloma
Abstract Number: 2127
Date and Time: 5:30 p.m. – 7:30 p.m., Saturday, December 3, 2016
Location: San Diego Convention Center, Hall GH

Presentation Title: piggyBac™-Produced CAR-T Cells Exhibit Stem-Cell Memory Phenotype
Abstract Number: 2167
Date and Time: 5:30 p.m. – 7:30 p.m., Saturday, December 3, 2016
Location: San Diego Convention Center, Hall GH

Presentation Title: Development of Novel Non-Immunoglobulin Centyrin-Based CARs (CARTyrins) Targeting Human BCMA
Abstract Number: 4557
Date and Time: 6:00 p.m. – 8:00 p.m., Monday, December 5, 2016
Location: San Diego Convention Center, Hall GH

About Poseida Therapeutics, Inc.

Poseida Therapeutics is translating best-in-class gene editing technologies into lifesaving treatments. The company is developing CAR T-cell immunotherapies for multiple myeloma and other cancer types, as well as gene therapies for orphan diseases. Poseida is also partnered with Janssen Biotech to develop allogeneic CAR T-cell therapies using Poseida’s gene editing platform. Poseida has assembled a suite of industry-leading gene editing technologies, including the piggyBac™ DNA Modification System, XTN™ TALEN and NextGEN™ CRISPR site-specific nucleases, and Footprint-Free™ Gene Editing (FFGE).  For more information, visit www.poseida.com.

Corporate Communications Contact:
Jason Spark
Canale Communications
619-849-6005
Jason@canalecomm.com